 , Agents producing tachycardia , Alkaloids , Autonomic Agents , Cholinergic Agents , Cholinergic Agonists , Cholinergic Nicotinic Agonist , Cytochrome P-450 CYP1A2 Inducers , Cytochrome P-450 CYP1A2 Inducers (strength unknown) , Cytochrome P-450 CYP1A2 Substrates , Cytochrome P-450 CYP2A6 Inhibitors , Cytochrome P-450 CYP2A6 Inhibitors (strength unknown) , Cytochrome P-450 CYP2A6 Substrates , Cytochrome P-450 CYP2B6 Substrates , Cytochrome P-450 CYP2C19 Substrates , Cytochrome P-450 CYP2C8 Substrates , Cytochrome P-450 CYP2C9 Substrates , Cytochrome P-450 CYP2D6 Substrates , Cytochrome P-450 CYP2E1 Inducers , Cytochrome P-450 CYP2E1 Inducers (strength unknown) , Cytochrome P-450 CYP2E1 Inhibitors , Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) , Cytochrome P-450 CYP2E1 Substrates , Cytochrome P-450 CYP3A Substrates , Cytochrome P-450 CYP3A4 Substrates , Cytochrome P-450 Enzyme Inducers , Cytochrome P-450 Enzyme Inhibitors , Cytochrome P-450 Substrates , Drugs Used in Addictive Disorders , Drugs Used in Nicotine Dependence , Ganglion Blockers , Ganglionic Stimulants , Miscellaneous Autonomic Drugs , Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates , Nervous System , Neurotransmitter Agents , Nicotine, antagonists & inhibitors , Nicotinic Agonists , OCT1 inhibitors , OCT2 Inhibitors , Peripheral Nervous System Agents , Pyridines , Smoking Cessation Agents , Solanaceous Alkaloids